Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

NCT06541405 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Interventions

DRUG: NK520

Sponsor

Base Therapeutics (Shanghai) Co., Ltd.

Collaborators

[object Object]